Ivosidenib–azacitidine dans les leucémies aiguës myéloïdes avec mutation IDH1 R132
Open Access
- 3 October 2023
- journal article
- editorial
- Published by Elsevier in Bulletin du Cancer
- Vol. 110 (12) , 1232-1233
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLBlood Advances, 2023
- A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.Journal of Clinical Oncology, 2022
- Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid LeukemiaNew England Journal of Medicine, 2022
- Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 MutationsClinical Cancer Research, 2022
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AMLNew England Journal of Medicine, 2018
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia GenomeNew England Journal of Medicine, 2009